上海透景生命科技股份有限公司 董事会议事规则 上海透景生命科技股份有限公司 董事会议事规则 第一章 总则 第一条 为明确上海透景生命科技股份有限公司（以下简称"公司"）董事会 的职责权限，规范董事会组织、董事行为及操作规则，充分发挥董事会的作用， 督促董事正确履行其权利和义务，完善公司的法人治理结构，根据《中华人民共 和国公司法》《中华人民共和国证券法》《深圳证券交易所创业板股票上市规则》 （以下简称"《上市规则》"）、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》及《上海透景生命科技股份有限公司章程》（简 称"《公司章程》"）等有关规定，特制定本规则，作为董事及董事会运作的行 为准则。 第二章 董事会的组成和职权 第二条 公司依法设立董事会，董事会受股东会的委托，负责经营和管理公司 的法人财产。董事会对股东会负责，在《公司章程》和股东会赋予的职权范围内 行使职权。 第三条 公司董事会由 7 名董事组成，其中独立董事 3 名，职工代表董事 1 名， 董事长 1 名。 董事可以由高级管理人员兼任，但兼任高级管理人员职务的董事以及由职工 代表担任的董事，总计不得超过公司董事总数的 1/ ...

上海透景生命科技股份有限公司 董事和高级管理人员行为准则 上海透景生命科技股份有限公司 董事和高级管理人员行为准则 第一章 总则 第一条 为了规范上海透景生命科技股份有限公司（以下简称"公司"）董 事和高级管理人员的行为，完善公司治理，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《深圳证券交易所创业板股票上市规则》（以下简称"《上市规则》"）、《深 圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》（以 下简称"《规范运作指引》"）等相关法律、法规、规范性文件以及《上海透景 生命科技股份有限公司章程》（以下简称"《公司章程》"）的规定，特制定本 行为准则。 第二条 本准则适用于公司的董事、高级管理人员。 第三条 公司董事、高级管理人员应自觉学习《公司法》《证券法》及国家 有关法律、法规、规范性文件，不断提高自身素质和修养，增强法律意识和现代 企业经营意识，掌握最新政策导向和经济发展趋势。 第四条 公司董事、高级管理人员应当诚实守信，不得损害投资者特别是中 小投资者的合法权益。 第二章 声明与承诺 第五条 公司董事和高级管理人员 ...

| | 法定代表人因为执行职务造成他人损害 | | --- | --- | | | 的，由公司承担民事责任。公司承担民事责任 | | | 后，依照法律或者本章程的规定，可以向有过 | | | 错的法定代表人追偿。 | | 第九条 公司全部资产分为等额股份，股东以其 | 第十条 股东以其认购的股份为限对公司承担 | | 认购的股份为限对公司承担责任，公司以其全部 | 责任，公司以其全部财产对公司的债务承担责 | | 资产对公司的债务承担责任。 | 任。 | | 第十条 本公司章程自生效之日起，即成为规范 | 第十一条 本公司章程自生效之日起，即成为规 | | 公司的组织与行为、公司与股东、股东与股东之 | 范公司的组织与行为、公司与股东、股东与股 | | 间权利义务关系的具有法律约束力的文件，对公 | 东之间权利义务关系的具有法律约束力的文 | | 司、股东、董事、监事、高级管理人员具有法律 | 件，对公司、股东、董事、高级管理人员具有 | | 约束力的文件。依据本章程，股东可以起诉股东， | 法律约束力。依据本章程，股东可以起诉股东， | | 股东可以起诉公司董事、监事、总经理和其他高 | 股东可以起诉公司董 ...

公司部分治理制度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300642 证券简称：透景生命 公告编号：2025-081 上海透景生命科技股份有限公司 关于拟变更注册地址、修订《公司章程》及修订、废止或制订 为进一步完善公司治理结构，更好地促进公司规范运作，根据《深圳证券交 易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》等法律法规、规范性文件及本次《公司章程》修订 的内容，结合公司实际情况，公司董事会同意对公司部分治理制度进行修订、废 止或制订，具体情况如下： | 变更前 | | 变更后 | | --- | --- | --- | | 上海市浦东新区汇庆路 412 | 号 | 上海市浦东新区凯庆路 126 号 | 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司 章程指引》、《关于新<公司法>配套制度规则实施相关过渡期安排》等法律法规、 规范性文件的规定，结合公司实际情况，公司拟调整内部治理结构，不再设置监 事会或者监事，原监事会行使的规定职权将由公司董事会审计委员 ...

证券代码：300642 证券简称：透景生命 公告编号：2025-080 上海透景生命科技股份有限公司 关于第四届董事会第十五次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、上海透景生命科技股份有限公司（以下简称"公司"）第四届董事会第 十五次（临时）会议（以下简称"本次会议"）通知于 2025 年 11 月 08 日通过 邮件的方式向公司全体董事送出。 2、本次会议于 2025 年 11 月 11 日在上海市浦东新区汇庆路 412 号公司会议 室以通讯会议的方式召开。 二、董事会会议审议情况 1、审议通过《关于拟变更注册地址并修订<公司章程>的议案》 根据公司经营发展和规划的需要，公司拟对注册地址进行变更。根据《公司 法》、《上市公司章程指引》、《关于新<公司法>配套制度规则实施相关过渡期 安排》等法律法规、规范性文件的规定，结合公司实际情况，公司拟调整内部治 理结构，不再设置监事会或者监事，原监事会行使的规定职权将由公司董事会审 计委员会行使，同时调整公司董事会席位结构，将 1 名非独立董事席位调整为职 工代表董 ...

Market Overview - The precision medicine sector experienced a decline of 1.77% on November 4, with TuoJing Life leading the drop [1][2] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable stock performances in the precision medicine sector included: - RenDu Bio (688193) closed at 52.90, up 1.05% with a trading volume of 7076.23 hands and a transaction value exceeding 36.99 million yuan [1] - TuoJing Life (300642) closed at 22.73, down 2.86% with a trading volume of 78,200 hands and a transaction value of 178 million yuan [2] - Other companies like DaAn Gene (002030) and Anke Bio (300009) showed minimal changes, with DaAn Gene remaining flat at 6.57 and Anke Bio down 0.55% to 10.84 [1][2] Capital Flow - The precision medicine sector saw a net outflow of 979 million yuan from institutional investors, while retail investors contributed a net inflow of 642 million yuan [2][3] - Specific stock capital flows indicated: - GuoMai Technology (002093) had a net inflow of 8.61 million yuan from institutional investors, while retail investors saw a net outflow of 15.98 million yuan [3] - TuoJing Life experienced minimal net inflow from institutional investors at 25,000 yuan, with retail investors also showing a slight outflow [3]

Investment & Contracts - Zhenyu Technology plans to invest RMB 2.11 billion in humanoid robot precision module and component projects in Ninghai County from 2025 to 2030, aiming to expand production capacity and enter emerging business areas [1] - East Asia Machinery intends to establish a smart manufacturing base for air compressors and core components in Hefei, Anhui Province, with a total investment of approximately RMB 400 million [5] - Hopu Co., Ltd.'s subsidiary signed a procurement contract for a 200MW/800MWh independent energy storage project with a total value of RMB 520 million, which is expected to positively impact future operating performance [7] Shareholding Changes - Tianhua New Energy's actual controllers plan to transfer 12.95% of shares to CATL at a price of RMB 24.49 per share, representing a 19% discount to the closing price [1] - Tianmai Technology's controlling shareholder will change from Guo Jianguo to Suzhou Qichen after transferring 17,756,720 shares at a price of RMB 30.52 per share, totaling approximately RMB 541.94 million [6] - Zhongyuan Co., Ltd. will see a change in actual control to Zhu Shuangquan, Zhu Shunquan, and Zhu Mengqian, with a combined voting rights of 25.63% after signing a voting rights entrustment agreement [3] Other Developments - Beisimei's actual controller is under investigation by the China Securities Regulatory Commission for failing to fulfill mandatory tender offer obligations and information disclosure violations, but this does not affect the company's operations [2] - InSai Group has decided to terminate its major asset restructuring plan to acquire 80% of Zhizhe Tongxing Brand Management Consulting (Beijing) Co., Ltd. due to changes in the external environment [4] - Taifu Pump Industry has also terminated its major asset restructuring plan to acquire at least 51% of Nanyang Huacheng's shares, as the parties could not reach an agreement [9] - Toukang Life has received one medical device registration certificate and eight registration applications for various products, enhancing its product line but with limited immediate impact on performance [8]

Core Points - The company, Tsinghua Tongfang, announced that it has received a medical device registration certificate from the Shanghai Municipal Drug Administration [2] - Additionally, the company has had eight medical device registration applications accepted by the National Medical Products Administration [2]

Core Viewpoint - The company, Transgenomic Life (300642.SZ), has received a medical device registration certificate from the Shanghai Municipal Drug Administration and has had eight medical device registration applications accepted by the National Medical Products Administration, which will enhance its product portfolio in the infection detection field, particularly for hepatitis B virus and respiratory infections [1] Group 1: Regulatory Approvals - The company has obtained one medical device registration certificate and had eight applications accepted, which are primarily focused on infection detection products [1] - The current approval stage is the acceptance of registration applications, with further evaluations and reviews required by the National Medical Products Administration [1] Group 2: Market Impact - The new medical device registration will enrich the company's flow cytometry product line and better meet clinical diagnostic needs for lung cancer detection [1] - The company’s enhanced capabilities in the in vitro diagnostic field are expected to positively impact its market expansion ability, although the actual sales and usage will depend on future market promotion effectiveness [1]

Core Viewpoint - The company, Transgenomic Life (300642.SZ), has received a medical device registration certificate from the Shanghai Municipal Drug Administration and has had eight medical device registration applications accepted by the National Medical Products Administration, focusing on infection detection products related to hepatitis B virus and respiratory infections, which will enhance the company's product matrix but will not impact recent performance [1] Group 1 - The company has obtained one medical device registration certificate and had eight applications accepted, which are primarily in the infection detection field [1] - The accepted products are related to hepatitis B virus and respiratory infections, which will enrich the company's product offerings [1] - The current approval stage is the acceptance of registration applications, with further evaluations and reviews required by the National Medical Products Administration [1] Group 2 - The 2024 edition of the Chinese Medical Association's guidelines for lung cancer indicates that serological tests can aid in assessing treatment efficacy and monitoring [1] - The acquisition of the medical device registration certificate will enhance the company's flow cytometry product line, better meeting clinical diagnostic needs for lung cancer detection [1] - This development is expected to strengthen the company's competitiveness in the in vitro diagnostic field and improve market expansion capabilities, although the actual sales impact remains uncertain [1]